

Amendments to the Claims:

1-25. (Canceled)

26. (Previously Presented) A bispecific tetravalent homodimeric F_v antibody formed by two single-chain F_v monomers, each of said F_v monomers having at least four variable domains, wherein said four variable domains are V_{H-A} , V_{L-A} , V_{H-B} and V_{L-B} , wherein V_{H-A} and V_{L-A} are V_H and V_L domains of an antibody specific for antigen A, respectively, and V_{H-B} and V_{L-B} are V_H and V_L domains of an antibody specific for antigen B, respectively;

V_{H-A} is linked to V_{L-B} by peptide linker 1, V_{L-B} is linked to V_{H-B} by peptide linker 2, V_{H-B} is linked to V_{L-A} by peptide linker 3; and

said peptide linker 1 and said peptide linker 3 are a peptide bond or have about 1 to about 10 amino acids; and said peptide linker 2 has 3 to about 10 amino acids.

27. (Previously Presented) The F_v antibody of Claim 26, wherein said peptide linker 1 and peptide linker 2 have the amino acid sequence GG.

28. (Previously Presented) The F_v antibody of Claim 26, wherein said peptide linker 2 comprises the amino acid sequence GPGGS.

29. (Previously Presented) The F_v antibody of Claim 26, wherein the antibody is bispecific for human CD3 and CD19.

30-31. (Canceled)